
SMTI Stock Forecast & Price Target
SMTI Analyst Ratings
Bulls say
Sanara MedTech Inc. has demonstrated significant growth in its surgical and soft tissue repair products, with sales increasing by 24% year-over-year to $23.4 million, largely driven by the strong demand for its CellerateRX Surgical Activated Collagen. Additionally, the company's revenue from bone fusion products has also seen a notable increase, rising 25% year-over-year to $3.1 million, indicating a healthy expansion across its product lines. The strategic focus on expanding distribution partners and penetrating healthcare facilities further supports a positive outlook for continued revenue growth in the upcoming quarters, with the potential for profitability in the near future.
Bears say
Sanara MedTech has reported net revenue of $26.3 million, reflecting a 21.5% year-over-year growth, albeit falling short of projections at $26.7 million. The company faces several significant risks, including lower-than-anticipated revenue growth, challenges in acquiring new customers, potential hurdles in launching new products or services, and risks of dilution. Additionally, the reduction of the EV/Revenue multiple from 4.3x to 3.0x indicates a reassessment of the company's valuation following the removal of telehealth from its business model, further contributing to a negative outlook.
This aggregate rating is based on analysts' research of Sanara MedTech Inc. and is not a guaranteed prediction by Public.com or investment advice.
SMTI Analyst Forecast & Price Prediction
Start investing in SMTI
Order type
Buy in
Order amount
Est. shares
0 shares